Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) announced its earnings results on Friday. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.02), Zacks reports. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo updated its FY 2026 guidance to 0.870-0.870 EPS.
Daiichi Sankyo Stock Down 11.5%
OTCMKTS:DSNKY traded down $2.09 during trading hours on Friday, hitting $16.14. The company’s stock had a trading volume of 92,402 shares, compared to its average volume of 391,487. The stock has a market capitalization of $30.07 billion, a P/E ratio of 17.17, a price-to-earnings-growth ratio of 3.10 and a beta of -0.17. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. The stock has a fifty day moving average of $16.52 and a 200-day moving average of $17.74. Daiichi Sankyo has a 52-week low of $14.98 and a 52-week high of $27.50.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on the stock. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research report on Thursday. Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. Two equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Daiichi Sankyo presently has a consensus rating of “Hold”.
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
See Also
- Five stocks we like better than Daiichi Sankyo
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
